Clinical Trial Update: Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating lesion dosimetry with Iodine-124 in metastatic thyroid cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• Iodine-124 (Iodine-124)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer | Phase 1 | Status: COMPLETED